Clinical Experience with 18F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen

Steven Rowe, Michael Gorin, Roberto A. Salas Fragomeni, Alexander Drzezga, Martin Gilbert Pomper

Research output: Contribution to journalArticle


Prostate cancer (PCa) is the most common noncutaneous malignancy diagnosed in men. Despite the large number of men who will suffer from PCa at some point during their lives, conventional imaging modalities for this important disease (contrast-enhanced computed tomography, bone scan, and MR imaging) have provided only marginal to moderate success in appropriately guiding patient management in certain clinical contexts. In this review, the authors discuss radiofluorinated small molecule radiotracers that have been developed to bind to the transmembrane glycoprotein prostate-specific membrane antigen, a target that is nearly universally overexpressed on PCa epithelial cells.

Original languageEnglish (US)
JournalPET Clinics
StateAccepted/In press - 2016


  • BAY 1075553
  • DCFPyL
  • Prostate cancer
  • Radiopharmaceutical

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Clinical Experience with <sup>18</sup>F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen'. Together they form a unique fingerprint.

  • Cite this